S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Closing prices for crude oil, gold and other commodities
Pipeline break spills 45,000 gallons of diesel in Wyoming
2 Important Retail Stock Battles to Watch
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Judge revives Obama-era ban on coal sales from federal lands
In Biden's big bill: Climate, health care, deficit reduction
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:DCPH

Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News

$16.41
+0.64 (+4.06%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$15.77
$16.43
50-Day Range
$10.43
$17.20
52-Week Range
$6.51
$17.33
Volume
755,528 shs
Average Volume
776,284 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.43

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
12.1% Downside
$14.43 Price Target
Short Interest
Bearish
15.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.66
Upright™ Environmental Score
News Sentiment
0.53mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$32,960 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.48) to ($2.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

1046th out of 1,117 stocks

Pharmaceutical Preparations Industry

511th out of 550 stocks

DCPH stock logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Analysts Set New Price Targets

Several analysts have issued reports on the company. SVB Leerink boosted their price objective on Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the stock an "outperform" rating in a report on Friday, August 5th. HC Wainwright boosted their price objective on Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, August 5th. Finally, JMP Securities upgraded Deciphera Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $23.00 price objective on the stock in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Deciphera Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $14.13.

Deciphera Pharmaceuticals Trading Up 4.1 %

Shares of DCPH opened at $16.41 on Friday. Deciphera Pharmaceuticals has a fifty-two week low of $6.51 and a fifty-two week high of $17.33. The business's 50-day moving average is $13.32 and its 200-day moving average is $10.78.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Rating) last issued its earnings results on Thursday, August 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.05. Deciphera Pharmaceuticals had a negative return on equity of 74.37% and a negative net margin of 231.99%. The company had revenue of $32.49 million for the quarter, compared to the consensus estimate of $30.11 million. During the same quarter in the prior year, the company earned ($1.21) EPS. The firm's quarterly revenue was up 37.8% on a year-over-year basis. Sell-side analysts predict that Deciphera Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

Deciphera Pharmaceuticals Tops Q1 EPS by 10c
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings
8/04/2022
Today
8/13/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.43
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
-12.1%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

Net Income
$-299,960,000.00
Net Margins
-231.99%
Pretax Margin
-236.57%

Debt

Sales & Book Value

Annual Sales
$96.15 million
Book Value
$6.06 per share

Miscellaneous

Free Float
64,082,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
1.11

Key Executives














DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2022?

9 analysts have issued 12-month price objectives for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $6.00 to $23.00. On average, they expect the company's stock price to reach $14.43 in the next year. This suggests that the stock has a possible downside of 12.1%.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2022?

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of the year. Since then, DCPH stock has increased by 68.0% and is now trading at $16.41.
View the best growth stocks for 2022 here
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) released its earnings results on Thursday, August, 4th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.05. The business earned $32.49 million during the quarter, compared to the consensus estimate of $30.11 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 74.37% and a negative net margin of 231.99%. Deciphera Pharmaceuticals's revenue for the quarter was up 37.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) earnings per share.

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.06%), Northern Trust Corp (0.65%), Healthcare of Ontario Pension Plan Trust Fund (0.24%), Rafferty Asset Management LLC (0.23%), UBS Group AG (0.15%) and Hennion & Walsh Asset Management Inc. (0.16%). Insiders that own company stock include Brightstar Associates Llc, Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, New Leaf Venture Management Ii, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $16.41.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.10 billion and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

The company employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.